LACE1 Inhibitors
Chemical inhibitors of LACE1 target various aspects of cellular metabolism and mitochondrial function to achieve inhibition. Oligomycin A, Antimycin A, Rotenone, TTFA, Sodium azide, Allopurinol, Bongkrekic acid, and Phenformin all disrupt the mitochondrial electron transport chain at different points, which is critical for ATP production. Oligomycin A specifically inhibits ATP synthase, directly reducing the ATP available for LACE1's energy-dependent functions. Similarly, Antimycin A and Rotenone obstruct complexes III and I, respectively, while TTFA targets complex II, all resulting in diminished ATP synthesis. Sodium azide acts on cytochrome c oxidase, which is a component of complex IV, further reducing ATP production. This decrease in ATP undercuts the energy supply essential for LACE1 activity. Allopurinol's inhibition of xanthine oxidase indirectly reduces ATP by altering purine metabolism, while Phenformin also inhibits mitochondrial complex I, mimicking Rotenone's effects on ATP synthesis and thus LACE1 inhibition.
Furthermore, CCCP and 2-Deoxy-D-glucose disrupt proton gradients and glycolysis, respectively, both of which are essential for maintaining adequate levels of ATP. CCCP collapses the proton gradient across the mitochondrial inner membrane, thereby inhibiting the ATP production necessary for LACE1. In parallel, 2-Deoxy-D-glucose hampers glycolysis, which is yet another critical pathway for ATP generation, essential for powering LACE1's activities. Atracurium Besilate induces calcium dysregulation, which can inhibit LACE1 since its activities are modulated by calcium concentrations. Concanamycin A specifically targets the V-ATPase that acidifies lysosomes, an environment where LACE1 operates. Inhibition of lysosome acidification by Concanamycin A thus inhibits LACE1's lysosomal functions. All these chemicals disrupt the energy balance and cellular conditions necessary for LACE1 to function, effectively inhibiting its activity within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Oligomycin A inhibits mitochondrial ATP synthase, leading to a reduction in ATP levels. LACE1 relies on ATP for its lysosomal and mitochondrial associated functions, thus inhibition of ATP synthesis by Oligomycin A would directly reduce LACE1 activity due to lack of energy substrate. | ||||||
Carbonyl Cyanide m-Chlorophenylhydrazone | 555-60-2 | sc-202984A sc-202984 sc-202984B | 100 mg 250 mg 500 mg | $77.00 $153.00 $240.00 | 8 | |
CCCP dissipates the proton gradient across the mitochondrial inner membrane, which indirectly inhibits ATP production essential for LACE1's activity. With ATP synthesis compromised, LACE1's ATP-dependent functions are inhibited. | ||||||
Antimycin A | 1397-94-0 | sc-202467 sc-202467A sc-202467B sc-202467C | 5 mg 10 mg 1 g 3 g | $55.00 $63.00 $1675.00 $4692.00 | 51 | |
Antimycin A inhibits mitochondrial complex III, disrupting electron transport and reducing ATP production. Reduced ATP levels would inhibit LACE1's ATP-dependent catalytic activities. | ||||||
Rotenone | 83-79-4 | sc-203242 sc-203242A | 1 g 5 g | $89.00 $259.00 | 41 | |
Rotenone inhibits mitochondrial complex I, leading to decreased electron transport and ATP synthesis. This depletion of ATP indirectly inhibits LACE1 function due to energy deprivation. | ||||||
2-Thenoyltrifluoroacetone | 326-91-0 | sc-251801 | 5 g | $37.00 | 1 | |
TTFA is an inhibitor of mitochondrial complex II, which would lead to a decrease in electron transport and consequently ATP synthesis. The resulting lower ATP levels would inhibit LACE1's ATP-dependent activities. | ||||||
Sodium azide | 26628-22-8 | sc-208393 sc-208393B sc-208393C sc-208393D sc-208393A | 25 g 250 g 1 kg 2.5 kg 100 g | $43.00 $155.00 $393.00 $862.00 $90.00 | 8 | |
Sodium azide inhibits cytochrome c oxidase in the mitochondrial electron transport chain, leading to reduced ATP synthesis. This indirect inhibition of ATP production can inhibit LACE1 activity due to energy shortage. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol inhibits xanthine oxidase, which can lead to altered purine metabolism and subsequently reduce ATP levels. This reduction in ATP can inhibit the energy-dependent functions of LACE1. | ||||||
Bongkrekic acid | 11076-19-0 | sc-205606 | 100 µg | $400.00 | 10 | |
Bongkrekic acid inhibits the adenine nucleotide translocator (ANT) in the mitochondria, preventing ADP/ATP exchange across the inner mitochondrial membrane. This action effectively inhibits ATP supply, thereby inhibiting LACE1's ATP-dependent functions. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A inhibits V-ATPase, which is responsible for acidifying lysosomes. Since LACE1 is associated with lysosomal function, inhibition of lysosome acidification would consequently inhibit LACE1's lysosome-related activities. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits glycolysis by competing with glucose, leading to decreased ATP production. This reduction in ATP availability would result in inhibition of LACE1's ATP-dependent functions. | ||||||